NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study
- PMID: 25633286
- PMCID: PMC4316430
- DOI: 10.1136/bmjopen-2014-006640
NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study
Abstract
Objectives: Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), low-dose aspirin and statins may decrease the risk of oesophageal adenocarcinoma (OAC) among patients with Barrett's oesophagus (BO). However, previous studies did not adequately address bias and confounding. Our objective was to estimate the risk of OAC among patients with BO exposed to NSAIDs, statins and PPIs.
Design: Case-control study nested within a BO cohort.
Setting: Two primary care databases (the UK and the Netherlands (NL)).
Participants: Cases were adults ≥18 years of age with OAC or high-grade dysplasia (HGD) diagnosis ≥1 year after BO diagnosis. Controls were matched on age, sex, year of BO diagnosis and database.
Exposure: Drug use was assessed from BO diagnosis until matching date.
Outcome measure: Adjusted ORs with 95% CI were calculated by conditional logistic regression.
Results: Within the BO cohort (n=15 134), 45 OAC (UK: 40, NL: 5) and 12 HGD cases (NL: 12) were identified. ORa for OAC during NSAID use was 1.2 (95% CI 0.6 to 2.5) and during statin use for >3 years 0.5 (95% CI 0.1 to 1.7). When including HGD cases (n=57), ORa for NSAID use was 0.9 (95% CI 0.5 to 1.8) and for statin use >3 years 0.5 (95% CI 0.1 to 1.7). Higher doses of statins showed lower estimates for OAC and HGD, though not statistically significant. Low-dose aspirin and PPIs did not significantly decrease the risk of OAC and HGD.
Conclusions: In this population-based nested case-control study, use of NSAIDs, PPIs, low-dose aspirin or statins did not reduce the risk of HGD and OAC among patients with BO. These findings indicate that for an unselected group of patients with BO chemoprevention by use of drugs to reduce progression to HGD and OAC should not be directly considered as routine care.
Keywords: EPIDEMIOLOGY.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Figures
Similar articles
-
Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.Aliment Pharmacol Ther. 2018 Aug;48(4):469-477. doi: 10.1111/apt.14895. Epub 2018 Jun 29. Aliment Pharmacol Ther. 2018. PMID: 29956826
-
Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis.Gut. 2014 Aug;63(8):1229-37. doi: 10.1136/gutjnl-2013-305997. Epub 2013 Nov 12. Gut. 2014. PMID: 24221456 Free PMC article.
-
Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.Eur J Gastroenterol Hepatol. 2012 Aug;24(8):917-23. doi: 10.1097/MEG.0b013e3283543f01. Eur J Gastroenterol Hepatol. 2012. PMID: 22569083
-
The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off.Aliment Pharmacol Ther. 2014 Jun;39(11):1321-30. doi: 10.1111/apt.12759. Epub 2014 Apr 16. Aliment Pharmacol Ther. 2014. PMID: 24738722
-
Epidemiology and prevention of oesophageal adenocarcinoma.Scand J Gastroenterol. 2022 Aug;57(8):891-895. doi: 10.1080/00365521.2022.2042594. Epub 2022 Mar 2. Scand J Gastroenterol. 2022. PMID: 35234549 Review.
Cited by
-
Development and validation of a novel risk prediction algorithm to estimate 10-year risk of oesophageal cancer in primary care: prospective cohort study and evaluation of performance against two other risk prediction models.Lancet Reg Health Eur. 2023 Aug 14;32:100700. doi: 10.1016/j.lanepe.2023.100700. eCollection 2023 Sep. Lancet Reg Health Eur. 2023. PMID: 37635924 Free PMC article.
-
Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview.Ann Gastroenterol. 2017;30(1):1-6. doi: 10.20524/aog.2016.0091. Epub 2016 Sep 30. Ann Gastroenterol. 2017. PMID: 28042232 Free PMC article. Review.
-
Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma.Therap Adv Gastroenterol. 2021 Aug 19;14:17562848211033730. doi: 10.1177/17562848211033730. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 34434254 Free PMC article. Review.
-
Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.J Cancer Res Clin Oncol. 2021 Sep;147(9):2681-2691. doi: 10.1007/s00432-021-03544-3. Epub 2021 Feb 11. J Cancer Res Clin Oncol. 2021. PMID: 33575855 Free PMC article.
-
Data Resource Profile: The Integrated Primary Care Information (IPCI) database, The Netherlands.Int J Epidemiol. 2022 Dec 13;51(6):e314-e323. doi: 10.1093/ije/dyac026. Int J Epidemiol. 2022. PMID: 35182144 Free PMC article. No abstract available.
References
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical